Investigating the utility of ‘global’ measures to quantify neuroimaging biomarkers across the Alzheimer's Disease trajectory

Abstract

Background: Alzheimer's Disease (AD) is characterized by β‐Amyloid (Aβ) and Tau deposition in brain regions essential for memory, learning, and cognition, followed by glucose hypometabolism and widespread brain atrophy ¹ . As such, these pathological processes are widely studied to assess their progression across disease stages.

The paper